Peptide and Oligonucleotide CDMO Market Size, Share & Industry Analysis, By Product (Peptides, Oligonucleotides) By Service (Contract Development, Contract Manufacturing), By End Use and Regional Forecast, 2026-2034

The peptide and oligonucleotide CDMO market size was valued at USD 3.07 Billion in 2025. The market is projected to grow from USD 3.32 Billion in 2026 to USD 6.27 Billion by 2034, exhibiting a CAGR of 8.26% during the forecast period.

The peptide and oligonucleotide CDMO market is gaining strong importance within the biopharmaceutical outsourcing industry as drug developers increasingly advance complex therapeutics based on peptides, antisense oligonucleotides, siRNA, mRNA-related components, and nucleic acid-based medicines. CDMO partners support pharmaceutical and biotechnology companies with process development, analytical testing, scale-up, regulatory documentation, and commercial manufacturing. Growing demand for targeted therapies, personalized medicines, metabolic disease treatments, oncology pipelines, and rare disease therapeutics is strengthening outsourcing demand. The peptide and oligonucleotide CDMO market Report highlights rising reliance on specialized manufacturing partners with technical expertise, GMP capabilities, and flexible production platforms.

Key Takeaways

Market Size & Growth

• Global market size 2025: USD 3.07 Billion
• Global market size 2034: USD 6.27 Billion
• CAGR (2026–2034): 8.26% 

Market Share – Regionals

• North America: 41% 
• Europe: 30%
• Asia-Pacific: 23% 
• Rest of World: 6%

Country-Level Shares

• Germany: 26% of Europe’s market 
• United Kingdom: 21% of Europe’s market
• Japan: 22% of Asia-Pacific market 
• China: 40% of Asia-Pacific market

Peptide And Oligonucleotide CDMO Market Latest Trends

The peptide and oligonucleotide CDMO market trends are increasingly shaped by demand for complex therapeutic modalities that require advanced synthesis, purification, and analytical capabilities. Pharmaceutical companies are expanding peptide and oligonucleotide pipelines, but many lack in-house infrastructure for large-scale production. This has increased reliance on CDMO partners offering solid-phase synthesis, liquid-phase synthesis, chromatography, lyophilization, impurity profiling, and regulatory-ready documentation.

Download Free sample to learn more about this report.

Another major trend is the shift toward integrated development and manufacturing partnerships. Drug developers prefer CDMOs that can support early research, clinical supply, process optimization, and commercial production under one service model. Demand is also rising for high-purity oligonucleotides, modified nucleic acids, peptide conjugates, and long-chain peptide manufacturing. The peptide and oligonucleotide CDMO market Forecast indicates continued innovation in automation, green chemistry, high-throughput analytics, and flexible GMP manufacturing as companies seek faster development timelines, stronger quality control, and reliable supply continuity.

Peptide And Oligonucleotide CDMO Market Dynamics

DRIVER

Rising Demand for Targeted Peptide and Oligonucleotide Therapeutics

The main driver supporting peptide and oligonucleotide CDMO market Growth is the increasing demand for targeted therapies that address complex diseases with greater specificity. Peptides and oligonucleotides are being explored across oncology, metabolic disorders, cardiovascular diseases, rare genetic conditions, infectious diseases, and neurological disorders. These molecules offer strong therapeutic potential because they can target disease pathways, proteins, RNA sequences, and cellular mechanisms with high precision. As clinical pipelines expand, pharmaceutical and biotechnology companies require specialized CDMO partners to manage complex manufacturing processes.

Peptide and oligonucleotide production demands technical expertise, advanced purification systems, strict quality control, and regulatory-compliant facilities. Outsourcing allows drug developers to reduce infrastructure investment while gaining access to experienced manufacturing teams. The Peptide Oligonucleotide CDMO industry analysis identifies rising pipeline complexity, increased biologic-like therapeutic development, and growing demand for scalable GMP manufacturing as major factors supporting long-term market expansion.

RESTRAINT

Complex Manufacturing Requirements and High Technical Barriers

A key restraint affecting the peptide and oligonucleotide CDMO market is the technical complexity involved in peptide and oligonucleotide development and manufacturing. These products require specialized synthesis chemistry, impurity control, analytical characterization, formulation expertise, and scale-up capabilities. Even minor process variations can affect product purity, stability, yield, and regulatory acceptability, creating significant operational challenges for CDMO providers and clients.

Manufacturing complexity also increases project timelines and requires highly skilled scientific personnel, advanced equipment, and validated production systems. Capacity constraints may occur when demand rises faster than qualified manufacturing availability. Regulatory expectations for impurity profiling, sequence verification, sterility assurance, and documentation can further complicate development. The peptide and oligonucleotide CDMO market Research Report highlights technical barriers, quality control challenges, and limited specialized capacity as restraints influencing outsourcing decisions and supplier selection.

OPPORTUNITY

Expansion of Rare Disease and Personalized Medicine Pipelines

A major opportunity within the peptide and oligonucleotide CDMO market lies in the rapid expansion of rare disease and personalized medicine pipelines. Oligonucleotide-based therapies are increasingly used to target genetic disorders, while peptide-based therapies are gaining traction in metabolic, endocrine, and oncology applications. These therapeutic areas often require specialized manufacturing strategies, flexible batch sizes, and rapid development support, creating strong opportunities for CDMO providers with advanced technical capabilities.

Biotechnology startups and emerging pharmaceutical companies frequently rely on CDMOs because they lack internal production infrastructure. CDMOs that offer end-to-end support from process development to GMP manufacturing can capture growing demand from innovative therapeutic developers. The peptide and oligonucleotide CDMO market opportunities are also expanding through peptide-drug conjugates, RNA-targeted therapeutics, modified oligonucleotides, and next-generation delivery systems. Providers investing in scalable capacity, analytical depth, and regulatory support are positioned to benefit from increasing outsourcing demand.

CHALLENGE

Capacity Limitations and Regulatory Compliance Pressure

One of the major challenges in the peptide and oligonucleotide CDMO market is balancing rising demand with limited specialized manufacturing capacity. Peptide and oligonucleotide production requires dedicated facilities, advanced synthesis platforms, highly trained teams, and strict contamination control practices. As more drug candidates enter clinical and commercial development, CDMOs face pressure to expand capacity while maintaining consistent quality and regulatory compliance.

Regulatory expectations continue to evolve for complex therapeutics, especially around impurity characterization, process validation, residual solvents, raw material control, and analytical method robustness. CDMOs must invest continuously in quality systems, digital documentation, and regulatory expertise. The Peptide Oligonucleotide CDMO industry report emphasizes that supplier reliability, manufacturing scalability, and compliance strength are becoming critical factors in client selection. Managing these challenges is essential for supporting long-term partnerships and maintaining competitive positioning.

Peptide And Oligonucleotide CDMO Market Segmentation

By Product

Peptides account for approximately 56% of the peptide and oligonucleotide CDMO market Share and remain the leading product segment due to their broad therapeutic use and mature development ecosystem. Peptide-based drugs are widely used in metabolic disorders, oncology, endocrinology, cardiovascular diseases, infectious diseases, and pain management. Their ability to provide selective biological activity makes them attractive for targeted therapy development. CDMO partners support peptide programs through custom synthesis, process optimization, scale-up, purification, lyophilization, formulation support, and GMP manufacturing. Demand is particularly strong for long-chain peptides, modified peptides, cyclic peptides, peptide-drug conjugates, and highly purified active pharmaceutical ingredients. Pharmaceutical companies rely on peptide CDMOs because production requires deep knowledge of synthesis chemistry, impurity control, and analytical validation. The peptide and oligonucleotide CDMO market analysis indicates that peptide outsourcing remains strong as drug developers seek faster timelines, flexible capacity, and reliable commercial supply. Increasing interest in obesity, diabetes, oncology, and rare disease therapeutics continues to strengthen peptide manufacturing demand. CDMOs offering integrated development, regulatory support, and high-volume manufacturing capabilities are gaining strong positioning within this segment.

Oligonucleotides represent approximately 44% of the peptide and oligonucleotide CDMO market Share and are expanding rapidly due to rising demand for RNA-targeted therapies, antisense oligonucleotides, siRNA, aptamers, and modified nucleic acid medicines. Oligonucleotide therapeutics are gaining attention because they can target genetic instructions and disease-driving RNA sequences with high precision. CDMO support is essential because oligonucleotide synthesis requires advanced solid-phase manufacturing, specialized phosphoramidite chemistry, purification, desalting, conjugation, analytical testing, and strict quality documentation. Demand is increasing from biotechnology companies developing treatments for rare genetic disorders, liver diseases, neurological conditions, oncology, and infectious diseases. The segment also benefits from growing investment in personalized medicines and precision therapeutics. The peptide and oligonucleotide CDMO market outlook highlights oligonucleotides as a high-value segment where technical expertise and manufacturing capacity are major competitive differentiators. CDMOs are expanding oligonucleotide production platforms to handle longer sequences, chemical modifications, GalNAc conjugates, and high-purity clinical-grade materials. As more oligonucleotide candidates advance toward late-stage development, demand for scalable GMP production and robust analytical capabilities continues to rise.

To know how our report can help streamline your business, Speak to Analyst

By Service

Contract Development accounts for approximately 38% of the peptide and oligonucleotide CDMO market Share and plays a critical role in early-stage peptide and oligonucleotide therapeutic development. This service category includes route scouting, process development, analytical method development, impurity identification, formulation support, scale-up planning, stability testing, and regulatory documentation preparation. Pharmaceutical and biotechnology companies increasingly outsource development work because peptide and oligonucleotide programs require specialized chemistry, advanced analytical capabilities, and strong technical knowledge before moving into clinical manufacturing. Contract development services are especially important for emerging biotech firms that need expert support but do not have internal infrastructure for complex synthesis and process optimization. Demand is strengthened by rising interest in targeted therapeutics, rare disease pipelines, RNA-based medicines, and peptide-drug conjugates. The peptide and oligonucleotide CDMO market analysis indicates that contract development remains a high-value service segment because strong early development decisions directly affect yield, purity, manufacturability, and regulatory readiness.

Contract Manufacturing represents approximately 62% of the peptide and oligonucleotide CDMO market Share and remains the leading service segment due to rising demand for GMP production, clinical supply, and commercial-scale manufacturing. Peptide and oligonucleotide manufacturing requires advanced synthesis platforms, purification systems, lyophilization capacity, quality control laboratories, and validated production environments. Drug developers increasingly rely on CDMOs to produce high-purity active pharmaceutical ingredients and finished intermediates while maintaining regulatory compliance and supply consistency. Contract manufacturing demand is particularly strong for long-chain peptides, chemically modified peptides, antisense oligonucleotides, siRNA, conjugated oligonucleotides, and highly specialized therapeutic molecules. The segment benefits from increasing clinical pipeline progression and growing commercialization of complex therapeutics. The Peptide Oligonucleotide CDMO industry analysis highlights contract manufacturing as the dominant service category because pharmaceutical companies need scalable, compliant, and technically advanced production partners to manage complex therapeutic supply requirements.

By End Use

Pharmaceutical companies account for approximately 46% of the peptide and oligonucleotide CDMO market Share and remain the largest end-use segment. Large pharmaceutical organizations outsource peptide and oligonucleotide development and manufacturing to expand production flexibility, reduce internal capacity pressure, and access specialized synthesis expertise. These companies manage broad therapeutic pipelines across metabolic diseases, oncology, cardiovascular disorders, rare diseases, and neurological conditions, creating strong demand for CDMO support across both development and commercial manufacturing stages. Outsourcing also helps pharmaceutical companies manage complex technical requirements such as impurity profiling, sequence confirmation, formulation optimization, stability assessment, and GMP documentation. The peptide and oligonucleotide CDMO market insights show that pharmaceutical companies increasingly prefer integrated CDMO partners that can support process development, clinical supply, regulatory support, and long-term commercial production under one relationship model.

Peptide And Oligonucleotide CDMO Market Regional Outlook

To get more information on the regional analysis of this market, Download Free sample

North America

North America remains the largest region in the peptide and oligonucleotide CDMO market due to its advanced biopharmaceutical ecosystem, strong biotechnology financing environment, and extensive pipeline of peptide and oligonucleotide therapeutics. Pharmaceutical and biotechnology companies across the region are increasingly outsourcing complex development and manufacturing activities to specialized CDMO partners that offer GMP facilities, advanced analytical systems, and strong regulatory experience. Demand is especially strong for peptide therapeutics used in metabolic diseases, oncology, and endocrine disorders, as well as oligonucleotide programs targeting rare genetic diseases and RNA-mediated conditions. The region also benefits from mature clinical development infrastructure, experienced scientific talent, and established outsourcing relationships between drug developers and manufacturing partners.

CDMOs in North America are investing in capacity expansion, automation, high-purity synthesis, and integrated development models to support rising demand from both large pharmaceutical companies and emerging biotech firms. The region also shows growing interest in supply chain resilience, local manufacturing access, and advanced quality systems. North America accounts for approximately 41% of the global peptide and oligonucleotide CDMO market Share, supported by strong innovation activity, clinical pipeline expansion, and high demand for specialized peptide and oligonucleotide manufacturing services.

Europe

Europe represents a major peptide and oligonucleotide CDMO market supported by strong pharmaceutical manufacturing heritage, advanced regulatory standards, and a well-developed biotechnology research base. The region has long-standing expertise in peptide synthesis, sterile manufacturing, analytical development, and complex active pharmaceutical ingredient production. Pharmaceutical and biotechnology companies across Europe increasingly outsource development and manufacturing activities to improve operational flexibility and access specialized infrastructure. Demand is supported by growing research activity in metabolic diseases, oncology, rare diseases, autoimmune disorders, and RNA-targeted therapies.

European CDMOs are expanding capabilities in high-potency peptides, long-chain peptide synthesis, modified oligonucleotides, and GMP-grade manufacturing. The region also benefits from strong quality expectations and established supply relationships with global pharmaceutical companies. Sustainability and green chemistry are becoming important themes as manufacturers seek more efficient solvent use, waste reduction, and responsible production processes. Europe accounts for approximately 30% of the global peptide and oligonucleotide CDMO market Share, supported by advanced manufacturing capabilities, strong regulatory credibility, and growing demand for integrated peptide and oligonucleotide development services.

Germany peptide and oligonucleotide CDMO market

Germany is one of Europe’s most important markets for peptide and oligonucleotide CDMO services due to its advanced pharmaceutical industry, strong chemical manufacturing capabilities, and high-quality research infrastructure. German pharmaceutical and biotechnology companies increasingly require specialized outsourcing support for process development, analytical validation, GMP manufacturing, and scale-up of complex therapeutic molecules. Demand is supported by strong activity in oncology, metabolic diseases, rare genetic disorders, and advanced biologic-like therapeutics. German organizations value CDMO partners with deep technical expertise, strong documentation standards, and reliable compliance performance.

The country’s established life sciences ecosystem supports continuous investment in advanced synthesis technologies, automation, and high-purity manufacturing. German customers often prioritize quality consistency, regulatory readiness, and long-term supply reliability when selecting peptide and oligonucleotide CDMO partners. Germany contributes approximately 26% of the European peptide and oligonucleotide CDMO market Share, reflecting its strong pharmaceutical manufacturing base, sophisticated research environment, and growing reliance on specialized outsourcing models.

United Kingdom peptide and oligonucleotide CDMO market

The United Kingdom is a significant market for peptide and oligonucleotide CDMO services, driven by a strong biotechnology ecosystem, academic research strength, and increasing therapeutic innovation. UK-based biotech companies and pharmaceutical developers increasingly outsource synthesis, development, analytical testing, and GMP manufacturing to specialized CDMO partners. Demand is especially strong among emerging companies developing oligonucleotide therapies, peptide therapeutics, rare disease candidates, and targeted treatment platforms. Outsourcing helps these firms access advanced technical capabilities while maintaining lean internal operations.

The UK market benefits from strong translational research, clinical development activity, and collaboration between academic institutions, biotechnology companies, and manufacturing partners. CDMOs serving UK clients are expected to provide flexible capacity, scientific consulting, robust quality systems, and regulatory-aware development support. The United Kingdom accounts for approximately 21% of the European peptide and oligonucleotide CDMO market Share, supported by innovation-led biotech activity, growing demand for outsourced development, and strong focus on advanced therapeutic modalities.

Asia-Pacific

Asia-Pacific is emerging as one of the fastest-expanding regions in the peptide and oligonucleotide CDMO market due to increasing pharmaceutical outsourcing, expanding biotechnology investment, and growing manufacturing capacity. Countries across the region are strengthening capabilities in peptide synthesis, oligonucleotide production, analytical testing, and GMP manufacturing to serve both domestic and international customers. The region benefits from competitive production capabilities, a growing scientific workforce, and increasing demand for targeted therapies. Pharmaceutical and biotechnology companies increasingly use Asia-Pacific CDMOs for cost-efficient development support, clinical supply, and large-scale manufacturing services.

Demand is supported by rising activity in metabolic diseases, oncology, infectious diseases, and rare disease therapeutics. CDMOs in the region are investing in automated synthesis platforms, quality systems, and advanced purification technologies to compete globally. Asia-Pacific accounts for approximately 23% of the global peptide and oligonucleotide CDMO market Share, supported by rapid biopharmaceutical development, expanding contract manufacturing infrastructure, and increasing participation in global therapeutic supply chains.

Japan peptide and oligonucleotide CDMO market

Japan represents a technologically advanced peptide and oligonucleotide CDMO market supported by strong pharmaceutical research, high healthcare standards, and growing interest in precision therapeutics. Japanese pharmaceutical companies are increasingly developing peptide and oligonucleotide-based candidates for oncology, metabolic diseases, rare disorders, and neurological conditions. Outsourcing demand is growing as companies seek specialized partners for process development, analytical characterization, and GMP manufacturing support. Japanese customers prioritize quality, reliability, and scientific accuracy, making advanced CDMO capabilities highly valuable.

The country’s aging population and demand for innovative therapies support continued research into targeted medicines. CDMO partnerships are becoming more important as molecules grow more complex and require specialized production technologies. Japan contributes approximately 22% of the Asia-Pacific peptide and oligonucleotide CDMO market Share, supported by advanced pharmaceutical research, strong regulatory discipline, and increasing adoption of outsourcing models for complex therapeutic development.

China peptide and oligonucleotide CDMO market

China is one of the most dynamic markets in the Peptide Oligonucleotide CDMO industry due to rapid expansion of biotechnology companies, strong pharmaceutical manufacturing investment, and growing global outsourcing demand. Chinese CDMOs are strengthening capabilities in peptide synthesis, oligonucleotide manufacturing, process development, analytical services, and GMP production. The country’s expanding biopharmaceutical sector is creating demand for both domestic and international peptide and oligonucleotide development support.

China’s CDMO industry benefits from increasing scientific talent, improving quality standards, and growing investment in advanced synthesis platforms. Demand is particularly strong in oncology, metabolic diseases, rare genetic disorders, and RNA-targeted therapies. Domestic biotechnology companies increasingly rely on CDMOs to accelerate early development and scale-up activities. China accounts for approximately 40% of the Asia-Pacific peptide and oligonucleotide CDMO market Share, supported by rapid biotech growth, expanding manufacturing capacity, and increasing demand for cost-effective high-quality outsourcing services.

Rest of World

The Rest of World region, including Latin America, the Middle East, and Africa, is gradually developing demand for peptide and oligonucleotide CDMO services as pharmaceutical research capability improves and healthcare innovation expands. While adoption remains lower than in North America, Europe, and Asia-Pacific, interest is increasing among regional pharmaceutical companies, academic institutions, and emerging biotechnology firms. These organizations often depend on established international CDMO partners for synthesis, development, analytical testing, and GMP manufacturing support due to limited local infrastructure.

Growth in this region is supported by increasing investment in pharmaceutical manufacturing, clinical research, and advanced therapeutics. Demand is strongest for small-batch development support, research-grade peptides, diagnostic oligonucleotides, and early-stage therapeutic programs. The Rest of World region accounts for approximately 6% of the global peptide and oligonucleotide CDMO market Share and presents long-term opportunities as regional life sciences ecosystems mature and demand for specialized outsourcing services increases.

List of Top Peptide Oligonucleotide CDMO Companies

• PolyPeptide Group
• STA Pharmaceutical Co. Ltd.
• Bachem
• Creative Peptides
• Aurigene Pharmaceutical Services Ltd.
• Merck KGaA
• EUROAPI
• Curia Global, Inc.
• CordenPharma
• Sylentis, S.A.

Top Two Companies with Highest Market Share

• Bachem – 17%
• PolyPeptide Group – 15%

Investment Analysis and Opportunities

The peptide and oligonucleotide CDMO market is witnessing substantial investment activity driven by the rapid expansion of peptide therapeutics, oligonucleotide medicines, RNA-targeted therapies, and precision medicine programs. Pharmaceutical and biotechnology companies are increasingly outsourcing development and manufacturing activities to specialized CDMOs capable of handling complex synthesis, purification, analytical characterization, and GMP production. As therapeutic pipelines expand, CDMOs are investing in manufacturing capacity expansion, automated synthesis technologies, advanced analytical laboratories, and large-scale purification systems to meet growing client demand.

The peptide and oligonucleotide CDMO market opportunities are particularly strong in rare disease therapies, oncology, metabolic disorders, neurological diseases, and genetic medicine applications. Growing interest in antisense oligonucleotides, siRNA, peptide-drug conjugates, and next-generation nucleic acid therapies is creating long-term outsourcing demand. Investment is also flowing into digital manufacturing platforms, process optimization technologies, and sustainable chemistry initiatives designed to improve efficiency and scalability. Companies capable of offering integrated development-to-commercialization services are positioned to benefit from increasing outsourcing preferences among both large pharmaceutical organizations and emerging biotechnology firms.

New Product Development

Innovation within the peptide and oligonucleotide CDMO market is focused on improving manufacturing efficiency, scalability, purity levels, and support for increasingly sophisticated therapeutic molecules. CDMOs are developing advanced synthesis platforms capable of producing longer peptide sequences, highly modified oligonucleotides, conjugated molecules, and complex therapeutic constructs. New manufacturing technologies are enabling better process control, reduced impurity levels, and improved batch consistency while supporting regulatory compliance requirements.

Another major area of development involves automation, continuous manufacturing concepts, advanced chromatography systems, and high-throughput analytical technologies. CDMOs are also introducing specialized services for peptide-drug conjugates, GalNAc-conjugated oligonucleotides, RNA-based therapeutics, and personalized medicine applications. The peptide and oligonucleotide CDMO market trends indicate increasing emphasis on integrated development models that combine process development, analytical support, GMP manufacturing, and regulatory assistance within a single service platform. These innovations are helping clients accelerate development timelines and improve commercialization readiness.

Five Recent Developments (2023–2025)

• Bachem expanded peptide manufacturing capacity to support increasing global demand for complex peptide therapeutics.
• PolyPeptide Group strengthened GMP production capabilities and expanded infrastructure for large-scale peptide manufacturing.
• CordenPharma increased investment in peptide and oligonucleotide development services to support advanced therapeutic pipelines.
• STA Pharmaceutical expanded integrated development and manufacturing capabilities for peptide and oligonucleotide customers.
• Curia Global enhanced specialized analytical and process development services supporting nucleic acid-based therapeutics.

Report Coverage

The peptide and oligonucleotide CDMO market Report provides comprehensive analysis of outsourcing trends, manufacturing technologies, competitive dynamics, service offerings, and therapeutic development activities shaping the industry. The report evaluates growing demand for peptide therapeutics, oligonucleotide medicines, RNA-based therapies, and targeted biologic-like molecules requiring specialized development and manufacturing support. It examines how pharmaceutical and biotechnology companies increasingly rely on CDMOs to accelerate development, improve scalability, and maintain regulatory compliance.

Request for Customization   to gain extensive market insights.

The peptide and oligonucleotide CDMO market Research Report includes detailed segmentation by product, service, end use, and regional performance. Product-level analysis covers peptides and oligonucleotides, while service segmentation evaluates contract development and contract manufacturing activities. End-use assessment includes pharmaceutical companies, biotechnology companies, and research institutions. The report also analyzes outsourcing trends, manufacturing expansion strategies, technological innovations, and capacity development initiatives influencing market competitiveness.

The Peptide Oligonucleotide CDMO industry report further provides regional analysis covering North America, Europe, Asia-Pacific, and Rest of World markets, including detailed evaluations of Germany, the United Kingdom, Japan, and China. The study delivers actionable peptide and oligonucleotide CDMO market insights, market analysis, market trends, market outlook, industry analysis, market opportunities, and Market Forecast information for investors, pharmaceutical manufacturers, biotechnology companies, contract service providers, and strategic decision-makers.